Clinical Trial Detail

NCT ID NCT02532231
Title Nivolumab in AML in Remission at High Risk for Relapse
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

acute myeloid leukemia

Therapies

Nivolumab

Age Groups: adult senior

Additional content available in CKB BOOST